

Table 1. Clinical characteristics by placenta size.

	SGA Placenta (n=12)	AGA Placenta (n=38)	LGA Placenta (n=17)	p
GA, mean weeks $\pm$ SD	37.96 $\pm$ 2.74	38.09 $\pm$ 1.74	37.90 $\pm$ 2.13	0.98
BW, mean g $\pm$ SD (range)	2538.4 $\pm$ 509.1	3000.9 $\pm$ 488.5	3039.9 $\pm$ 548.9	0.02*
AGA, n (%)	6 (50.0)	36 (94.7)	24 (88.9)	0.0005*
SGA	6 (50.0)	1 (2.6)	2 (7.4)	<0.0001*
LGA	0	1 (2.6)	1 (3.7)	0.80
Infant sex, male, n(%)	4 (33.3)	19 (51.4)	13 (48.2)	0.55
Maternal age, years, mean $\pm$ SD	30.6 $\pm$ 5.3	28.3 $\pm$ 5.3	30.8 $\pm$ 4.4	0.12
Maternal BMI, mean $\pm$ SD	27.9 $\pm$ 8.0	31.6 $\pm$ 6.7	28.8 $\pm$ 5.3	0.37
Nulliparous, n(%)	2 (16.7)	7 (18.9)	0	0.06
Prenatal care, n(%)	12 (100.0)	24 (68.6)	17 (68.0)	0.08
Alcohol use during pregnancy, n(%)	0	1 (2.6)	4 (14.8)	0.09
Cigarette use, n(%)	5 (41.7)	16 (42.1)	17 (63.0)	0.21
Mental health disorders, any, n(%)	7 (58.3)	24 (63.2)	18 (66.7)	0.88
In rehabilitation program, n(%)	8 (66.7)	17 (44.7)	8 (29.6)	0.09
Amphetamine use during pregnancy, n(%)	2 (16.7)	23 (60.5)	21 (77.8)	0.002*
Benzodiazepine, n(%)	1 (8.3)	4 (10.5)	1 (3.7)	0.60
Buprenorphine, n(%)	3 (25.0)	12 (31.6)	5 (18.5)	0.50
Methadone, n(%)	6 (50.0)	14 (36.8)	12 (44.4)	0.67

Cocaine, n(%)	1 (8.3)	3 (7.9)	2 (7.4)	0.99
Fentanyl, n(%)	3 (25.0)	12 (31.6)	16 (59.3)	0.04*
Heroin, n(%)	2 (16.7)	7 (18.4)	8 (29.6)	0.49
Morphine, n(%)	2 (16.7)	4 (10.5)	3 (11.1)	0.84
Multidrug (≥ 2) exposure, n(%)	6 (50.0)	30 (78.9)	23 (85.2)	0.05*
Positive urine toxicology screen in infant, n(%)	5 (41.7)	30 (78.9)	26 (96.3)	0.0004*
Positive meconium toxicology screen, n(%)	1 (8.3)	17 (44.7)	12 (44.4)	0.01*
Highest Finnegan score before initiation of medications, mean $\pm$ SD	8.3 $\pm$ 4.8	11.9 $\pm$ 4.1	13.1 $\pm$ 3.1	0.05*
DOL medications started, mean $\pm$ SD	2.8 $\pm$ 3.2	2.0 $\pm$ 1.5	2.3 $\pm$ 2.4	0.77
Days on medications, mean $\pm$ SD	6.8 $\pm$ 15.8	15.4 $\pm$ 17.2	18.6 $\pm$ 17.4	0.13

